1. Search Result
Search Result
Results for "

NTRK

" in MedChemExpress (MCE) Product Catalog:

33

Inhibitors & Agonists

1

Biochemical Assay Reagents

3

Inhibitory Antibodies

39

Recombinant Proteins

7

Antibodies

9

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-131003
    Taletrectinib
    2 Publications Verification

    DS-6051b; AB-106; IBI-344

    ROS Kinase Cancer
    Taletrectinib (DS-6051b) is a potent, orally active, and next-generation selective ROS1/NTRK inhibitor. Taletrectinib potently inhibits recombinant ROS1, NTRK1, NTRK2, and NTRK3 with IC50s of 0.207, 0.622, 2.28, and 0.98 nM, respectively. Taletrectinib also inhibits ROS1 G2032R and other Crizotinib-resistant ROS1 mutants .
    Taletrectinib
  • HY-W070306

    PDK-1 FGFR Wee1 MARK Neurological Disease Cancer
    PDK1-IN-1 (Compound 2-11) is a PDK1 inhibitor. PDK1-IN-1 is also useful as inhibitor of other kinases such as FGFR3, NTRK3, RP-S6K and WEE1. PDK1-IN-1 selectively inhibits microtubule affinity regulating kinase (MARK). PDK1-IN-1 can be used for researches of myeloproliferative disorders, cancer and Alzheimer's disease .
    PDK1-IN-1
  • HY-RS09631

    Small Interfering RNA (siRNA) Others

    NTRK2 Human Pre-designed siRNA Set A contains three designed siRNAs for NTRK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    NTRK2 Human Pre-designed siRNA Set A
    NTRK2 Human Pre-designed siRNA Set A
  • HY-RS09634

    Small Interfering RNA (siRNA) Others

    NTRK3 Human Pre-designed siRNA Set A contains three designed siRNAs for NTRK3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    NTRK3 Human Pre-designed siRNA Set A
    NTRK3 Human Pre-designed siRNA Set A
  • HY-131003A

    DS-6051b free base; AB-106 free base; IBI-344 free base

    ROS Kinase Cancer
    Taletrectinib (DS-6051b) free base is a potent, orally active, and next-generation selective ROS1/NTRK inhibitor. Taletrectinib free base potently inhibits recombinant ROS1, NTRK1, NTRK2, and NTRK3 with IC50s of 0.207, 0.622, 2.28, and 0.98 nM, respectively. Taletrectinib free base also inhibits ROS1 G2032R and other Crizotinib-resistant ROS1 mutants .
    Taletrectinib free base
  • HY-E70870

    Trk Receptor Neurological Disease
    TRKB(NTRK2) is a member of tyrosine kinase gene family. TRKB is the primary receptor for brain-derived nerve growth factor (BDNF) and neurotrophin 4/5 (NT4/5). TRKB(NTRK2) Recombinant Human Active Protein Kinase is a recombinant TRKB(NTRK2) protein that can be used to study TRKB(NTRK2)-related functions .
    TRKB(NTRK2) Recombinant Human Active Protein Kinase
  • HY-E70869

    Trk Receptor Neurological Disease
    TRKA (also named NTRK1) is a potential new member of the tyrosine kinase gene family. TRKA is a receptor tyrosine kinase that is phosphorylated in response to NGF. A single transmembrane domain divides TRKA into an extracellular domain, important for NGF binding, and an intracellular tyrosine kinase domain, important for signal transduction. TRKA(NTRK1) Recombinant Human Active Protein Kinase is a recombinant TRKA(NTRK1) protein that can be used to study TRKA(NTRK1)-related functions .
    TRKA(NTRK1) Recombinant Human Active Protein Kinase
  • HY-W700297

    KPI-285

    VEGFR Others
    K-106 (KPI-285) is a VEGFR antagonist that also inhibits neurotrophic tyrosine kinase receptors (NTRK). K-106 can be used for retinal research .
    K-106
  • HY-144321

    Trk Receptor Cancer
    Trk-IN-9 (Compound 12) is a potent inhibitor of TRK. Trk-IN-9 inhibits the proliferation of Km-12 cell lines. Trk-IN-9 induces the apoptosis of Km-12 cells in a concentration-dependent manner. Trk-IN-9 inhibits the phosphorylation of TRK to block downstream pathways. Trk-IN-9 has the potential for the research of NTRK-fusion cancers .
    Trk-IN-9
  • HY-P991098

    Trk Receptor Neurological Disease
    Anti-TrkB/NTRK2 Antibody is a human antibody expressed in CHO cells, targeting TrkB. Anti-TrkB/NTRK2 Antibody can be referenced as Human IgG2 kappa, Isotype Control (HY-P99002).
    Anti-TrkB/NTRK2 Antibody
  • HY-RS09632

    Small Interfering RNA (siRNA) Others

    Ntrk2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ntrk2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Ntrk2 Mouse Pre-designed siRNA Set A
    Ntrk2 Mouse Pre-designed siRNA Set A
  • HY-RS09635

    Small Interfering RNA (siRNA) Others

    Ntrk3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ntrk3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Ntrk3 Mouse Pre-designed siRNA Set A
    Ntrk3 Mouse Pre-designed siRNA Set A
  • HY-RS09636

    Small Interfering RNA (siRNA) Others

    Ntrk3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Ntrk3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Ntrk3 Rat Pre-designed siRNA Set A
    Ntrk3 Rat Pre-designed siRNA Set A
  • HY-RS09630

    Small Interfering RNA (siRNA) Others

    Ntrk1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Ntrk1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Ntrk1 Rat Pre-designed siRNA Set A
    Ntrk1 Rat Pre-designed siRNA Set A
  • HY-RS09629

    Small Interfering RNA (siRNA) Others

    Ntrk1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ntrk1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Ntrk1 Mouse Pre-designed siRNA Set A
    Ntrk1 Mouse Pre-designed siRNA Set A
  • HY-RS09628

    Small Interfering RNA (siRNA) Others

    NTRK1 Human Pre-designed siRNA Set A contains three designed siRNAs for NTRK1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    NTRK1 Human Pre-designed siRNA Set A
    NTRK1 Human Pre-designed siRNA Set A
  • HY-RS09633

    Small Interfering RNA (siRNA) Others

    Ntrk2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Ntrk2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Ntrk2 Rat Pre-designed siRNA Set A
    Ntrk2 Rat Pre-designed siRNA Set A
  • HY-161819

    Trk Receptor Cancer
    TRK-IN-29 (Compound B31) is a second-generation TRK inhibitor (IC50: 9 nM, 0.6 nM, 18 nM, 5 nM, 6 nM for TRKA G595R, TRKA F589L, TRKA G667C, TRKA and TRKC respectively). TRK-IN-29 inhibits the phosphorylation of TRKA. TRK-IN-29 has good antiproliferative activities against NTRK fusion positive cells. TRK-IN-29 has exellent plasma stability and moderate pharmacokinetic properties .
    TRK-IN-29
  • HY-163004

    Trk Receptor Cancer
    Type II TRK inhibitor 2 (compound 40l) is a selective type II TRK inhibitor with plasma stability and moderate hepatic microsomal stability. Type II TRK inhibitor 2 significantly inhibits Km-12, Ba/F3-TRKA G595R and Ba/F3-TRKA G667C cell proliferation (IC50: 4.1 nM, 41.5 nM, 1.4 nM). Type II TRK inhibitor 2 can be used to study NTRK fusion cancers .
    Type II TRK inhibitor 2
  • HY-156086

    Trk Receptor Cancer
    TRK-IN-24 (compound 10g) is a Trk Receptor inhibitor that inhibits TRKA, TRKC, TRKA G595R, TRKA G667C and TRKA F589L IC50s are 5.21, 4.51, 6.77, 1.42 and 6.13 nM respectively. TRK-IN-24 has antitumor efficacy in BaF3-CD74-NTRK1 G595R and BaF3-CD74-NTRK1 G667C xenograft models. TRK-IN-24 inhibits the proliferation of Ba/F3 cells transfected with single mutants such as SF, GK, and xDFG, with an IC50 of 1.43-47.56 nM .
    TRK-IN-24
  • HY-120393

    Trk Receptor Cancer
    GZ-389988 is a potent pan-TRK inhibitor with IC50 values ​​of 0.3, 0.1, and 0.5 nM for TRKA, TRKB, and TRKC, respectively. GZ-389988 can be used to study NTRK fusion-positive tumors .
    GZ-389988
  • HY-144451

    Trk Receptor Cancer
    TRK-IN-12 (Compound 9e) is a potent inhibitor of TRK (TRK G595R IC50 = 13.1 nM). TRK-IN-12 is a macrocyclic derivative compound. TRK-IN-12 shows significant antiproliferative activity in the Ba/F3-LMNA-NTRK1 cell line (IC50 = 0.080 μM). TRK-IN-12 has shown a better inhibitory effect (IC50 = 0.646 μM) than control agent LOXO-101 in Ba/F3-LMNA-NTRK1-G595R cell line .
    TRK-IN-12
  • HY-P990589

    BXL-1H5

    Trk Receptor Inflammation/Immunology
    GBR-900 is a humanized antibody expressed in CHO that targets TrkA/NTRK1. GBR-900 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for GBR-900 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
    GBR-900
  • HY-150561

    Trk Receptor Cancer
    Trk-IN-20 is a kind of 3-vinylindazole derivatives. Trk-IN-20 suppresses Trk kinases functions by phosphorylation inhibition of TrkA/B/C with IC50 values of 1.6 nM, 2.9 nM and 2.0 nM, respectively .
    Trk-IN-20
  • HY-185545

    Ligands for Target Protein for PROTAC Trk Receptor Cancer
    NTRK1-ligand-1 (Compound 15) is a NTRK1 ligand. NTRK1-ligand-1 serves as a Ligand for Target Protein for PROTAC, which is applicable to the development and design of PROTAC NTRK1 degraders, such as PROTAC NTRK1 degrader-1 (HY-181052). NTRK1-ligand-1 can be used in the research of solid tumors .
    NTRK1-ligand-1
  • HY-181052

    PROTACs Trk Receptor Cancer
    PROTAC NTRK1 degrader-1 is a wild-type and mutant NTRK1 PROTAC degrader with IC50 values of 4 nM (wild-type), 2 nM (G595R), 5 nM (G667C), and <0.5 nM (F598L). PROTAC NTRK1 degrader-1 catalyzes ubiquitination and subsequent proteasome-mediated degradation of wild-type and mutant (G595R, G667C, F598L) NTRK1. PROTAC NTRK1 degrader-1 can be used for the research of solid tumors .
    PROTAC NTRK1 degrader-1
  • HY-180172

    Trk Receptor Apoptosis Cancer
    TRK-IN-33 is a TRK inhibitor. TRK-IN-33 exhibits excellent TRKA G667C degradation (DC50 = 24.69 nM; Dmax > 90%), while sparing the wild-type protein in virto. TRK-IN-33 shows antiproliferative activities against Ba/F3-LMNA-NTRK1 G667C cells with an IC50 value of 2.48 nM. TRK-IN-33 effectively inhibits tumor growth and enhances apoptosis in tumor tissues with no apparent toxicity in vivio. TRK-IN-33 can be used for NTRK fusion−positive cancers research .
    TRK-IN-33
  • HY-101977A

    (R,S)-LOXO-195

    Trk Receptor Cancer
    (R,S)-Selitrectinib (compound 17) is a Trk inhibitor with activity against cancers harboring Trk inhibitor-resistant point mutations in NTRK1, NTRK2, or NTRK3 genes. (R,S)-Selitrectinib can be used for the research of trk inhibitor-resistant cancer .
    (R,S)-Selitrectinib
  • HY-W1115186

    Ligands for E3 Ligase Others
    CRBN ligand-900 is an E3 ligase ligand that can be used in the recruitment of CRBN protein. CRBN ligand-900 can be connected to the NTRK1 ligand (HY-185545) by a linker to synthesis of PROTAC NTRK1 degrader-1 (HY-181052) .
    CRBN ligand-900
  • HY-P992308

    Trk Receptor Inflammation/Immunology
    Anti-TrkC Antibody is a monoclonal antibody targeting TrkC/NTRK3. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-TrkC Antibody, please refer to Human IgG2 kappa, Isotype Control (HY-P99002).
    Anti-TrkC Antibody
  • HY-185546

    E3 Ligase Ligand-Linker Conjugates Others
    CRBN ligand-900 Gly is a synthesized E3 ligase ligand-linker conjugate (E3 Ligase Ligand-Linker Conjugate) that incorporates a CRBN ligand and a linker. CRBN ligand-900 Gly can be connected to the target protein ligand to form a PROTAC NTRK1 degrader-1 (HY-181052) .
    CRBN ligand-900 Gly
  • HY-115541

    Epigenetic Reader Domain JAK FLT3 RET ROS Kinase PDGFR FGFR c-Myc STAT Apoptosis PARP Cancer
    BRD4-IN-41 is a BRD4 inhibitor with an IC50 of 34 nM. BRD4-IN-41 also inhibits JAK2, FLT3, RET, ROS1, NTRK3, PDGFRb, and FGFR1 kinases with IC50 values ranging from 0.9 nM to 43 nM. BRD4-IN-41 inhibits acetyl-lysine binding site of BRD4, downregulates c-MYC, reduces phosphorylated STAT3 levels, induces G1 cell cycle arrest and apoptosis, thereby inhibiting cancer cells growth. BRD4-IN-41 can be used for the research of cancer, such as multiple myeloma and acute myeloid leukemia .
    BRD4-IN-41
  • HY-183116

    Molecular Glues Anaplastic lymphoma kinase (ALK) Cancer
    TRI-611 is a brain-penetrant, orally active molecular glue degrader targeting ALK. TRI-611 engages ALK via a distal degron, forms a ternary complex with CRBN, triggers ALK polyubiquitination and degradation, including TKI-resistant ALK fusion proteins. TRI-611 inhibits ALK downstream signaling pathways, induces anti-proliferative effects in ALK-positive cancer cells. TRI-611 induces regression of ALK-positive non-small cell lung cancer tumors in preclinical xenograft models. TRI-611 can be used for the research of ALK-positive non-small cell lung cancer, including TKI-refractory tumors and central nervous system metastases .
    TRI-611

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: